血管紧张素转化酶2
血管紧张素转化酶2(英語:Angiotensin-converting enzyme 2,ACE2;人類的ACE2常被稱為hACE2[5]),在人類基因組中由X染色體上的基因編碼,是一種表現於肺、動脈、心臟、腎臟與腸道等組織細胞表面的膜蛋白,為血管紧张素转化酶(ACE)的一個旁系同源體。
ACE2的主要功能為切割多肽,其多肽酶結構域位於細胞膜外側,一般在細胞膜上作用,可被脫落酶切割後脫離細胞、自組織間移除。ACE2可分別將血管紧张素I和血管紧张素II轉化为血管收縮素(1-9)和血管收縮素(1-7)[6][7],因而在心血管組織中有抗氧化與抗發炎等功能,在肺臟中可避免肺組織的損傷,在骨骼肌中或许能抑制肌肉纖維化。ACE2的表現可緩解許多心血管疾病的症狀,其表現量的下降則與這些疾病相關,有研究嘗試開發體外合成的人重組ACE2(rhACE2)為這些疾病的一種藥物。除切割多肽外,ACE2還有若干和多肽酶無關的功能。
ACE2还被SARS-CoV、SARS-CoV-2(屬乙型冠狀病毒)和人類冠狀病毒NL63(屬甲型冠狀病毒)等冠狀病毒用作感染細胞的受体[8],這些病毒刺突蛋白的受体结合域[9](RBD,receptor binding domain)可結合ACE2,進而使病毒進入細胞內。三種病毒的RBD均與ACE2的相同區域結合,但NL63病毒的RBD結構和另兩者差異較大,與ACE2的結合應為趨同演化的結果,且結合力較另外兩種病毒弱。SARS相關病毒也並非皆以ACE2為感染細胞的受體,SARS-CoV-2支系的共祖可能具有和ACE2結合的能力,此支系的病毒又與SARS-CoV支系的病毒發生重組,使部分SARS-CoV相關病毒也獲得此能力。
結構
[编辑]血管紧张素转化酶2(ACE2)最早於2000年自cDNA基因庫中發現,為血管紧张素转化酶(ACE)第一個被發現的旁系同源體[6],ACE2的基因位於人類基因組中的X染色體,包括18個外顯子,編碼的蛋白由805個胺基酸組成,與ACE的胺基酸序列相似度為42%[10]。ACE2是一個帶有鋅離子的金屬蛋白,屬單次跨膜蛋白(第一型膜蛋白),其N端結構域為一M2多肽酶,位於細胞膜外側,可再細分為I與II兩個子結構域(由一個α螺旋相連)[11];C端則與TMEM27[註 1]同源,包括疏水的跨膜結構域和一個胺基酸轉運體結構域,位於細胞內[12]。
ACE2因有跨膜區域而造成其結構測定的困難,過去僅知其N端多肽酶的結構,直到2020年科學家才用低溫電子顯微鏡測出了與另一蛋白B0AT1[註 2]結合狀態的完整ACE2結構,發現兩個ACE2和兩個B0AT1組成一複合體,複合體中兩個ACE2有交互作用,B0AT1間則無交互作用,僅與鄰近的ACE2作用,因此研究人員推測細胞膜上的ACE2也可能會形成二聚體[13][14]。
切割機理
[编辑]ACE2的活性位點有一個鋅離子(位於多肽酶的子結構域I),和ACE2的兩個組胺酸、一個麩胺酸與一個水分子錯合,切割多肽時,錯合的水分子作為一親核基,進攻多肽的羰基,形成四面體形的中間產物,並將質子轉移到麩胺酸上,此時組胺酸上的氫離子轉移到要被切除的胺基酸之胺基上,隨後肽鍵斷裂,此胺基酸作為離去基從中間產物脫離,並從麩胺酸處獲得氫離子[11]。
表現組織
[编辑]人體幾乎所有器官組織都有表現血管紧张素转化酶(ACE),而血管紧张素转化酶2(ACE2)則表現於II型肺泡細胞、小腸腸上皮細胞、血管內皮細胞、棕色脂肪組織[15]、血管平滑肌細胞、腎臟上皮細胞、睪丸組織與胎盤組織等[16][17],腦部許多神經元與膠細胞可能也有表現ACE2[10][18]。多數組織中ACE2的轉錄都是由一個較接近其基因的啟動子起始,但肺臟中ACE2基因的轉錄多起始於一個較遠的啟動子,兩啟動子轉錄出的mRNA5端序列稍有不同[19][20]。
功能
[编辑]切割多肽
[编辑]| 血管紧张素转化酶2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 标识符 | |||||||||
| 酶学委员会编号(EC编号) | 3.4.17.23 | ||||||||
| 数据库 | |||||||||
| 集成关系酶学数据库(IntEnz) | IntEnz总观 | ||||||||
| 不伦瑞克酶学数据库(BRENDA) | BRENDA进入 | ||||||||
| 专家蛋白质分析系统(ExPASy) | NiceZyme总观 | ||||||||
| 京都基因与基因组百科全书(KEGG) | KEGG进入 | ||||||||
| 元代谢途径数据库(MetaCyc) | 代谢途径 | ||||||||
| PRIAM酶功能特异性谱 | 谱档案 | ||||||||
| 蛋白质数据库(PDB)结构 | 结构生物信息学研究合作实验室PDB PDB欧洲 PDB概述 | ||||||||
| |||||||||
血管紧张素转化酶2主要的功能是與血管紧张素转化酶(ACE)拮抗,ACE可將無活性的血管收縮素Ⅰ切割成血管收縮素II,後者可促進抗利尿激素與醛固酮的分泌,以及刺激血管平滑肌收縮,使血壓上升;ACE2則分解血管收縮素Ⅰ和血管收縮素II以抑制其作用,將其C端的胺基酸移除,分別將前者轉化成血管收縮素(1-9),將後者轉化成血管收縮素(1-7)[註 3],其中切割血管收縮素II比切割血管收縮素I的能力高出許多,切割的產物中,血管收縮素(1-9)的功能不明,血管收縮素(1-7)則可刺激一氧化氮合成、抑制MAPK/ERK途徑與TGFβ途徑、以及抑制活性氧物質的生成,因此在心血管組織中有抗氧化與抗發炎等功能[10][13]。許多研究結果顯示ACE2表現量的下降與數種心血管疾病相關[22]。
肺泡細胞表現的ACE2有保護肺組織的功能。血管收縮素II可促進肺泡細胞凋亡與肺纖維化[23],因此ACE2將其分解可保護肺免於損傷[24],加上血管收縮素(1-7)可與MAS1受體結合,啟動下游反應以抑制血管收縮素II的作用[24][25]。
在骨骼肌中,血管收縮素II與血管收縮素(1-7)均有重要功能。血管收縮素II透過多種途徑降低肌肉蛋白質的合成,包括抑制Akt-mTOR途徑、促進肌萎缩素1與肌环指蛋白1的合成、生成活性氧物質而活化胱天蛋白酶途徑使細胞凋亡等,肌肉蛋白合成與分解的失衡會造成肌肉萎縮與肌纖維化等症狀[26][27],因此將血管收縮素II被轉化成血管收縮素(1-7)可停止其作用,且後者還可與MAS1受體結合,活化另一條反應途徑而抑制肌纖維化[13][28]。相較之下ACE2在骨骼肌的直接影響還有待更多研究闡明,有初步研究結果顯示在萎縮的肌肉組織中,ACE2可能可降低纖維化[13][29]。
在大腦中,ACE2切割血管收縮素II可能可抑制神經發炎,具神經保護的功能[30][31]。
除了切割血管收縮素II外,ACE2還可切割強啡肽A、apelin-13[32]、apelin-36、去精胺酸緩激肽(des-Arg(9) bradykinin)、β-酪啡肽、β澱粉樣蛋白[33]等其他多肽[20][34][16]。
其他
[编辑]除了切割多肽外,ACE2還有些與其蛋白酶活性無關的功能。有研究顯示ACE2可與整合素結合,有助於細胞黏附[13][35]。此外ACE2還參與了B0AT1的膜囊泡運輸過程,為其伴護蛋白,與B0AT1形成一複合體,協助將其轉運至細胞膜上[14]。在小腸上皮細胞的膜上,ACE2會與B0AT1結合形成異源二聚體,穩定其結構以促進小腸吸收氨基酸[16][36]。
移除
[编辑]ACE2的跨膜結構域可被ADAM17脱落酶切割,將其胞外部分釋放到血液中,進而從組織間移除[37][38],此過程受到許多調控,例如有一種鈣調蛋白可與ACE2結合以抑制ADAM17的切割[39],血管收縮素II也可促進ADAM17的活性,把會將其分解的ACE2移除[40],另外許多病理狀況、發炎反應也可促進ADAM17對ACE2的切割。脫落酶的切割會造成心血管組織中ACE2的流失、血液中ACE2(即sACE2)的濃度升高,因此後者可當作心臟衰竭、心房顫動、動脈粥樣硬化、慢性腎臟病、心肌梗塞、中風與糖尿病等多種疾病的生物標記[13][41][42]。
冠狀病毒受體
[编辑]
血管紧张素转化酶2被許多冠狀病毒用來當作感染細胞的受體,包括造成普通感冒的人類冠狀病毒NL63(屬甲型冠狀病毒)[43]、與MERS-CoV關係接近的祖魯棕蝠冠狀病毒(NeoCoV)[44]、造成SARS的SARS-CoV[45][46]和造成COVID-19的SARS-CoV-2(屬乙型冠狀病毒)[47]等,這些病毒刺突蛋白S1結構域中的受體結合結構域(receptor binding domain;RBD)和ACE2胞外的區域結合後,刺突蛋白可能被細胞表面的跨膜丝氨酸蛋白酶2(TMPRSS2)切割,促使病毒外膜和宿主細胞膜融合而讓病毒進入細胞質[48];此外SARS-CoV與SARS-CoV-2[49]還可能在不被TMPRSS2切割的情況下,與ACE2受體一起藉由內吞作用進入細胞,隨後其刺突蛋白在溶體中被組織蛋白酶切割後,再從溶體進入細胞質中[50][51][52]。ACE2的表現量與SARS-CoV-2的感染力皆由鼻腔到下呼吸道逐漸遞減,鼻腔可能是此病毒主要複製增殖的部位[16][53]。SARS-CoV-2感染可以多種途徑(調控基因表現、活化ADAM17脱落酶等)導致細胞膜上的ACE2表現量下降,造成腎素-血管收縮素系統失衡[30][54][55],且可能與COVID-19重症的症狀有關[16]。
SARS-CoV與SARS-CoV-2的RBD結構相似,胺基酸序列相似度為72%,SARS-CoV的RBD和ACE2結合時,與其直接接觸的胺基酸共有16個,其中8個位點在SARS-CoV-2中為對應相同胺基酸[56]。SARS-CoV-2的RBD與ACE2結合最為重要的位點為白胺酸455、苯丙胺酸486、麩醯胺酸493、絲胺酸494、天門冬醯胺501與酪氨酸505[57],與ACE2的結合力高於SARS-CoV[58]。SARS-CoV-2後續的變異株(Alpha、Beta、Gamma、Theta)因RBD序列發生出現N501Y突變而強化與ACE2的結合力;Omicron變異株的RBD發生了更多突變位點,其中有些增強、有些則減弱與ACE2的結合力[59];後來出現的Omicron亞型XBB.1.5變異株進一步發生S486P突變,增強與ACE2的結合力,可能是XBB.1.5取代其他Omicron亞型而成為主要流行毒株的原因之一[16][60]。人類冠狀病毒NL63之RBD則與前兩者的結構差異較大,卻能和ACE2的同一區域結合,為趨同演化的結果,但NL63和ACE2的結合力較弱,可能是其感染症狀較輕微的原因之一[56]。
而SARS相關病毒亦非皆以ACE2為感染細胞的受體,SARSr-CoV中,使用ACE2為受體的病毒株包含SARS-CoV支系的果子狸SARS冠狀病毒、WIV1、SHC014、WIV16、LYRa11、Rs4874、Rs7327等(以上病毒的RBD序列可再分成兩支),以及SARS-CoV-2支系的RaTG13和穿山甲冠狀病毒,上述以ACE2為受體的蝙蝠病毒皆是在中國雲南省發現;SARS-CoV支系的YNLF_31C、YNLF_34C、BtKY72、BM48-31、16BO133、HKU3、Rm1和Rf1等,以及SARS-CoV-2支系的RmYN02之RBD則應無法與ACE2結合,而是使用其他蛋白作為感染的受體,這些病毒株的RBD大多具有兩段序列缺失,可能因此影響和ACE2結合的能力[註 4][61]。SARSr-CoV中,與ACE2的結合能力應為多次起源,有學者提出SARS-CoV-2支系病毒的共祖可能可和ACE2結合(RmYN02則是後來才喪失了此能力),後來某個SARS-CoV-2支系的病毒曾和SARS-CoV支系的病毒發生重組,造成部分SARS-CoV支系的病毒也獲得了和ACE2結合的能力[61]。
應用
[编辑]由於ACE2的表現可緩解許多心血管疾病的症狀,已有研究嘗試將體外合成的ACE2(人重組ACE2;rhACE2)用於治療急性呼吸窘迫症候群(ARDS)[62]、肺動脈高壓(PAH)[63]與COVID-19重症等疾病[64][65][66],且因ACE2為SARS-CoV-2使用的受體,人重組ACE2還可能用作誘餌受體,使病毒無法結合細胞表面的ACE2而阻斷其感染[16]。另外也有研究試圖尋找能提升ACE2切割效率的小分子藥物[67],已知有三氮脒等化合物可能促進ACE2活性,但目前尚無以ACE2為標的的藥物被批准使用[30]。
小鼠模型實驗顯示針對ACE2的單株抗體或單域抗體可阻止SARS-CoV-2與ACE2結合,因而抑制其感染[68][69][70]。
演化
[编辑]早期的脊索動物已具有ACE2,海鞘(尾索動物)與文昌魚(頭索動物)皆尚無血管紧张素等肾素-血管紧张素系统的多數蛋白,但已具有ACE與ACE2[71]。脊椎動物(魚類、兩生類、爬行類、鳥類與哺乳類)皆具有ACE2,且其結構的保守度很高[56]。此外有些細菌(如柑橘潰瘍病菌)具有和ACE同源的蛋白,體外實驗結果顯示其具有將血管紧张素I切割成血管紧张素II的能力[72],以各生物中的ACE與ACE2序列製作的系統發生樹顯示細菌ACE與海鞘、文昌魚的ACE2關係較為接近,可能是由海鞘的ACE2經水平基因轉移至細菌基因組中[71]。
有研究分析哺乳類的ACE2序列,發現有4%的位點(皆位於具有酵素活性的結構域)正發生定向選擇[73]。
註腳
[编辑]参考文献
[编辑]- ^ 1.0 1.1 1.2 GRCh38: Ensembl release 89: ENSG00000130234 – Ensembl, May 2017
- ^ 2.0 2.1 2.2 GRCm38: Ensembl release 89: ENSMUSG00000015405 – Ensembl, 2017年5月
- ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Kasmi Y, Khataby K, Souiri A. Coronaviridae: 100,000 Years of Emergence and Reemergence. Ennaji MM (编). Emerging and Reemerging Viral Pathogens. Volume 1: Fundamental and Basic Virology Aspects of Human, Animal and Plant Pathogens. Elsevier. 2019: 135 [2021-03-04]. ISBN 978-0-12-819400-3. (原始内容存档于2020-07-24).
- ^ 6.0 6.1 Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.. Circ Res. 2000, 87 (5): E1–9 [2021-02-23]. PMID 10969042. doi:10.1161/01.res.87.5.e1. (原始内容存档于2021-05-04).
- ^ Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007, 73 (3): 463–9 [2008-12-11]. PMID 17049503. (原始内容存档于2009-01-23).
- ^ Weiss SR, Navas-Martin S. Angiotensin-converting enzyme 2--a new cardiac regulator. Microbiol Mol Biol Rev. 2005, 69 (4): 635–64. PMID 16339739.
- ^ 沈媚, 陈冰清, 于瑞嵩, 朱于敏, 李震. 冠状病毒S蛋白及其受体的结构和功能. 微生物学通报. 2017, 44 (10): 2452-2462 [2021-09-12]. (原始内容存档于2022-05-02).
- ^ 10.0 10.1 10.2 Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system.. Trends Endocrinol Metab. 2004, 15 (4): 166–9 [2021-03-04]. PMC 7128798
. PMID 15109615. doi:10.1016/j.tem.2004.03.001. (原始内容存档于2021-03-04).
- ^ 11.0 11.1 Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T; et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis.. J Biol Chem. 2004, 279 (17): 17996–8007. PMID 14754895. doi:10.1074/jbc.M311191200.
- ^ Turner AJ. Chapter 25: ACE2 Cell Biology, Regulation, and Physiological Functions. Unger T, Ulrike M, Steckelings UM, dos Santos RA (编). The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications. Academic Press. 2015: 185–189. ISBN 978-0-12-801364-9. doi:10.1016/B978-0-12-801364-9.00025-0.
- ^ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 Yamamoto K, Takeshita H, Rakugi H. ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19.. Clin Sci (Lond). 2020, 134 (22): 3047–3062 [2021-03-04]. PMC 7687025
. PMID 33231620. doi:10.1042/CS20200486. (原始内容存档于2021-03-04).
- ^ 14.0 14.1 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.. Science. 2020, 367 (6485): 1444–1448 [2021-03-04]. PMC 7164635
. PMID 32132184. doi:10.1126/science.abb2762. (原始内容存档于2021-03-04).
- ^ Cao, Xi; Shi, Ting-Ting; Zhang, Chuan-Hai; Jin, Wan-Zhu; Song, Li-Ni; Zhang, Yi-Chen; Liu, Jing-Yi; Yang, Fang-Yuan; Rotimi, Charles N; Xu, Aimin; Yang, Jin-Kui. ACE2 pathway regulates thermogenesis and energy metabolism. eLife. 2022-01-11, 11. ISSN 2050-084X. PMC 8776250
. PMID 35014608. doi:10.7554/eLife.72266
.
- ^ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 Oudit, Gavin Y.; Wang, Kaiming; Viveiros, Anissa; Kellner, Max J.; Penninger, Josef M. Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic. Cell. 2023, 186 (5): 906–922 [2026-10-19]. PMC 9892333
. PMID 36787743. doi:10.1016/j.cell.2023.01.039
.
- ^ Hikmet, Feria; Méar, Loren; Edvinsson, Åsa; Micke, Patrick; Uhlén, Mathias; Lindskog, Cecilia. The protein expression profile of ACE2 in human tissues. Molecular Systems Biology. 2020-07-01, 16 (7). ISSN 1744-4292. PMC 7383091
. PMID 32715618. doi:10.15252/msb.20209610
.
- ^ Kabbani, Nadine; Olds, James L. Does COVID19 infect the brain? If so, smokers might be at a higher risk. Molecular Pharmacology. 1 April 2020, 97 (5): 351–353. PMC 7237865
. PMID 32238438. doi:10.1124/molpharm.120.000014.
- ^ Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E. The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs.. Biochim Biophys Acta. 2013, 1829 (11): 1225–35 [2021-03-04]. PMC 3838857
. PMID 24100303. doi:10.1016/j.bbagrm.2013.09.007. (原始内容存档于2021-03-04).
- ^ 20.0 20.1 Jia H, Yue X, Lazartigues E. ACE2 mouse models: a toolbox for cardiovascular and pulmonary research.. Nat Commun. 2020, 11 (1): 5165 [2021-03-04]. PMC 7560817
. PMID 33057007. doi:10.1038/s41467-020-18880-0. (原始内容存档于2021-03-04).
- ^ Domenig O, Manzel A, Grobe N, Königshausen E, Kaltenecker CC, Kovarik JJ; et al. Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney.. Sci Rep. 2016, 6: 33678. PMC 5030486
. PMID 27649628. doi:10.1038/srep33678.
- ^ Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics.. J Cardiovasc Pharmacol. 2007, 50 (2): 112–9 [2021-03-04]. PMID 17703127. doi:10.1097/FJC.0b013e3180986219. (原始内容存档于2021-03-04).
- ^ Uhal BD, Li X, Xue A, Gao X, Abdul-Hafez A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis.. Am J Physiol Lung Cell Mol Physiol. 2011, 301 (3): L269–74 [2021-03-04]. PMC 3174737
. PMID 21665960. doi:10.1152/ajplung.00222.2010. (原始内容存档于2021-03-04).
- ^ 24.0 24.1 Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2.. Front Cell Infect Microbiol. 2020, 10: 317. PMC 7294848
. PMID 32582574. doi:10.3389/fcimb.2020.00317.
- ^ Gopallawa I, Uhal BD. Angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2.. Am J Physiol Lung Cell Mol Physiol. 2016, 310 (3): L240–8 [2021-02-24]. PMC 4888557
. PMID 26637635. doi:10.1152/ajplung.00187.2015. (原始内容存档于2021-04-13).
- ^ Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle.. Med Res Rev. 2015, 35 (3): 437–63 [2021-02-24]. PMID 25764065. doi:10.1002/med.21343. (原始内容存档于2022-01-09).
- ^ Winslow MA, Hall SE. Muscle wasting: A review of exercise, classical and non-classical RAS axes.. J Cell Mol Med. 2019, 23 (9): 5836–5845 [2021-02-24]. PMC 6714228
. PMID 31273946. doi:10.1111/jcmm.14412. (原始内容存档于2023-08-23).
- ^ Morales MG, Abrigo J, Meneses C, Cisternas F, Simon F, Cabello-Verrugio C. Expression of the Mas receptor is upregulated in skeletal muscle wasting.. Histochem Cell Biol. 2015, 143 (2): 131–41 [2021-03-04]. PMID 25208653. doi:10.1007/s00418-014-1275-1. (原始内容存档于2021-03-04).
- ^ Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA; et al. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.. PLoS One. 2014, 9 (4): e93449 [2021-03-04]. PMC 3973684
. PMID 24695436. doi:10.1371/journal.pone.0093449. (原始内容存档于2021-03-04).
- ^ 30.0 30.1 30.2 Orzeł, Urszula; Wójcik, Emilia; Filipek, Sławomir; Moreira, Irina S. ACE2 dysregulation and lipid metabolism: Mechanistic interplay between COVID-19 and neurodegeneration. Molecular Aspects of Medicine. 2026, 112: 101519. doi:10.1016/j.mam.2026.101519
.
- ^ Bennion, Douglas M.; Haltigan, Emily; Regenhardt, Robert W.; Steckelings, U. Muscha; Sumners, Colin. Neuroprotective Mechanisms of the ACE2–Angiotensin-(1-7)–Mas Axis in Stroke. Current Hypertension Reports. 2015, 17 (2) [2026-10-19]. ISSN 1522-6417. PMC 4378688
. PMID 25620630. doi:10.1007/s11906-014-0512-2
.
- ^ Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC; et al. [Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.. Front Neurosci. 2017, 11: 92 [2021-03-04]. PMC 5329011
. PMID 28293165. doi:10.3389/fnins.2017.00092. (原始内容存档于2021-03-04).
- ^ Liu, Shuyu; Liu, Junjun; Miura, Yukie; Tanabe, Chiaki; Maeda, Tomoji; Terayama, Yasuo; Turner, Anthony J.; Zou, Kun; Komano, Hiroto. Conversion of Aβ43 to Aβ40 by the successive action of angiotensin‐converting enzyme 2 and angiotensin‐converting enzyme (PDF). Journal of Neuroscience Research. 2014, 92 (9): 1178–1186 [2026-10-19]. ISSN 0360-4012. doi:10.1002/jnr.23404
.
- ^ Nicholls J, Peiris M. Good ACE, bad ACE do battle in lung injury, SARS.. Nat Med. 2005, 11 (8): 821–2. PMC 7095949
. PMID 16079870. doi:10.1038/nm0805-821.
- ^ Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes.. Biochem Pharmacol. 1975, 24 (17): 1639–41 [2021-03-04]. doi:10.1371/journal.pone.0034747. (原始内容存档于2021-03-04).
- ^ Hashimoto, Tatsuo; Perlot, Thomas; Rehman, Ateequr; Trichereau, Jean; Ishiguro, Hiroaki; Paolino, Magdalena; Sigl, Verena; Hanada, Toshikatsu; et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation (PDF). Nature. 2012-07-26, 487 (7408): 477–481 [2026-10-19]. ISSN 0028-0836. PMC 7095315
. PMID 22837003. doi:10.1038/nature11228
.
- ^ Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). The Journal of Biological Chemistry. August 2005, 280 (34): 30113–9. PMID 15983030. doi:10.1074/jbc.M505111200.
- ^ Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. Journal of Molecular and Cellular Cardiology. January 2014, 66: 167–76. PMID 24332999. doi:10.1016/j.yjmcc.2013.11.017.
- ^ Lambert DW, Clarke NE, Hooper NM, Turner AJ. Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain.. FEBS Lett. 2008, 582 (2): 385–90. PMC 7094239
. PMID 18070603. doi:10.1016/j.febslet.2007.11.085.
- ^ Patel, Vaibhav B.; Clarke, Nicola; Wang, Zuocheng; Fan, Dong; Parajuli, Nirmal; Basu, Ratnadeep; Putko, Brendan; Kassiri, Zamaneh; Turner, Anthony J.; Oudit, Gavin Y. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. Journal of Molecular and Cellular Cardiology. 2014, 66: 167–176 [2026-10-19]. doi:10.1016/j.yjmcc.2013.11.017
.
- ^ Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.. Circ Res. 2016, 118 (8): 1313–26 [2021-03-04]. PMC 4939482
. PMID 27081112. doi:10.1161/CIRCRESAHA.116.307708. (原始内容存档于2021-03-04).
- ^ McGurk, Kathryn A.; Curran, Lara; Sau, Arunashis; Ng, Fu Siong; Halliday, Brian; Ware, James S.; O’Regan, Declan P. Circulating Cardiovascular Proteomic Associations With Genetics and Disease. Circulation: Genomic and Precision Medicine. 2025, 18 (6). ISSN 2574-8300. PMC 12711284
. PMID 41054850. doi:10.1161/CIRCGEN.124.005005
.
- ^ Gene: ACE2, angiotensin I converting enzyme 2. National Center for Biotechnology Information (NCBI). U.S. National Library of Medicine. 2020-02-28 [2021-02-22]. (原始内容存档于2014-12-24).
- ^ Xiong, Q., Cao, L., Ma, C.; et al. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Nature. 2022, 612: 748–757. doi:10.1038/s41586-022-05513-3.
- ^ Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. Methods in Molecular Biology 1282. Springer New York. 2015: 1–23. ISBN 978-1-4939-2437-0. PMC 4369385
. PMID 25720466. doi:10.1007/978-1-4939-2438-7_1. Many α-coronaviruses utilize aminopeptidase N (APN) as their receptor, SARS-CoV and HCoV-NL63 use angiotensin-converting enzyme 2 (ACE2) as their receptor, MHV enters through CEACAM1, and the recently identified MERS-CoV binds to dipeptidyl-peptidase 4 (DPP4) to gain entry into human cells (See Table 1 for a list of known CoV receptors).
- ^ Li F. Receptor recognition and cross-species infections of SARS coronavirus. Antiviral Research. October 2013, 100 (1): 246–54. PMC 3840050
. PMID 23994189. doi:10.1016/j.antiviral.2013.08.014.
- ^ What are the official names of the disease and the virus that causes it?. Q&A on coronaviruses. World Health Organization. [22 February 2020]. (原始内容存档于2020-03-05).
- ^ Akhmerov Akbarshakh; Marban Eduardo. COVID-19 and the Heart. Circulation Research. 2020, 0 (10): 1443–1455. PMC 7188058
. PMID 32252591. doi:10.1161/CIRCRESAHA.120.317055.
- ^ Ou X, Liu Y, Lei X, Li P, Mi D, Ren L; et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.. Nat Commun. 2020, 11 (1): 1620 [2021-03-04]. PMC 7100515
. PMID 32221306. doi:10.1038/s41467-020-15562-9. (原始内容存档于2021-03-04).
- ^ Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Research. February 2008, 18 (2): 290–301. PMC 7091891
. PMID 18227861. doi:10.1038/cr.2008.15.
- ^ Millet JK, Whittaker GR. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology. April 2018, 517: 3–8. PMC 7112017
. PMID 29275820. doi:10.1016/j.virol.2017.12.015.
- ^ Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S; et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.. J Biol Chem. 2006, 281 (6): 3198–203 [2021-03-04]. PMID 16339146. doi:10.1074/jbc.M508381200. (原始内容存档于2021-03-04).
- ^ Hou, Yixuan J.; Okuda, Kenichi; Edwards, Caitlin E.; Martinez, David R.; Asakura, Takanori; Dinnon, Kenneth H.; Kato, Takafumi; Lee, Rhianna E.; et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020, 182 (2): 429–446.e14 [2026-10-19]. PMC 7250779
. PMID 32526206. doi:10.1016/j.cell.2020.05.042
.
- ^ Gao, Xiang; Zhang, Shengyuan; Gou, Jizhou; Wen, Yanling; Fan, Lujie; Zhou, Jian; Zhou, Guangde; Xu, Gang; Zhang, Zheng. Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. Journal of Infection. 2022, 85 (4): 418–427 [2026-10-19]. PMC 9250808
. PMID 35793758. doi:10.1016/j.jinf.2022.06.030
.
- ^ Wang, Kaiming; Gheblawi, Mahmoud; Nikhanj, Anish; Munan, Matt; MacIntyre, Erika; O’Neil, Conar; Poglitsch, Marko; Colombo, Daniele; Del Nonno, Franca; Kassiri, Zamaneh; Sligl, Wendy; Oudit, Gavin Y. Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries. Hypertension. 2022, 79 (2): 365–378 [2026-10-19]. ISSN 0194-911X. doi:10.1161/HYPERTENSIONAHA.121.18295.
- ^ 56.0 56.1 56.2 Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV.. Biochem Biophys Res Commun. 2020. PMC 7092824
. PMID 32081428. doi:10.1016/j.bbrc.2020.02.071.
- ^ Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.. Nat Med. 2020, 26 (4): 450–452 [2021-03-04]. PMC 7095063
. PMID 32284615. doi:10.1038/s41591-020-0820-9. (原始内容存档于2021-03-04).
- ^ Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A; et al. Cell entry mechanisms of SARS-CoV-2.. Proc Natl Acad Sci U S A. 2020, 117 (21): 11727–11734 [2021-03-04]. PMC 7260975
. PMID 32376634. doi:10.1073/pnas.2003138117. (原始内容存档于2021-12-10).
- ^ Han, Pengcheng; Li, Linjie; Liu, Sheng; Wang, Qisheng; Zhang, Di; Xu, Zepeng; Han, Pu; Li, Xiaomei; Peng, Qi; Su, Chao; Huang, Baihan; Li, Dedong; Zhang, Rong; Tian, Mingxiong; Fu, Lutang; Gao, Yuanzhu; Zhao, Xin; Liu, Kefang; Qi, Jianxun; Gao, George F.; Wang, Peiyi. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell. 2022, 185 (4): 630–640.e10 [2026-10-19]. PMC 8733278
. PMID 35093192. doi:10.1016/j.cell.2022.01.001
.
- ^ Yue, Can; Song, Weiliang; Wang, Lei; Jian, Fanchong; Chen, Xiaosu; Gao, Fei; Shen, Zhongyang; Wang, Youchun; Wang, Xiangxi; Cao, Yunlong. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. The Lancet Infectious Diseases. 2023, 23 (3): 278–280 [2026-10-19]. PMC 9897732
. PMID 36746173. doi:10.1016/S1473-3099(23)00010-5
.
- ^ 61.0 61.1 61.2 Wells, H L; Letko, M; Lasso, G; Ssebide, B; Nziza, J; Byarugaba, D K; Navarrete-Macias, I; Liang, E; et al. The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus. Virus Evolution. 2021. ISSN 2057-1577. doi:10.1093/ve/veab007.
- ^ Khan, Akram; Benthin, Cody; Zeno, Brian; Albertson, Timothy E.; Boyd, John; Christie, Jason D.; Hall, Richard; Poirier, Germain; Ronco, Juan J.; Tidswell, Mark; Hardes, Kelly; Powley, William M.; Wright, Tracey J.; Siederer, Sarah K.; Fairman, David A.; Lipson, David A.; Bayliffe, Andrew I.; Lazaar, Aili L. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care. 2017, 21 (1). ISSN 1364-8535. PMC 5588692
. PMID 28877748. doi:10.1186/s13054-017-1823-x
.
- ^ Shah, Aangi J.; Beckmann, Taylor; Vorla, Mounica; Kalra, Dinesh K. New Drugs and Therapies in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2023-03-19, 24 (6): 5850. ISSN 1422-0067. PMC 10058689
. PMID 36982922. doi:10.3390/ijms24065850
.
- ^ Li, Guangyao; Qian, Kewen; Zhang, Shuyi; Fu, Wenyan; Zhao, Jian; Lei, Changhai; Hu, Shi. Engineered soluble ACE2 receptor: Responding to change with change. Frontiers in Immunology. 2023-01-18, 13. ISSN 1664-3224. PMC 9891289
. PMID 36741399. doi:10.3389/fimmu.2022.1084331
.
- ^ Mirabito Colafella, Katrina M.; Uijl, Estrellita; Jan Danser, A.H. Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches: 523–530. 2019. doi:10.1016/B978-0-12-801238-3.65341-2.
- ^ Feng, Han; Yang, Linpu; Yang, Hang; Cheng, Dongwan; Li, Min; Song, Eli; Xu, Tao. A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion. Molecular Therapy. 2024, 32 (1): 218–226. doi:10.1016/j.ymthe.2023.11.019
.
- ^ Kulemina, Lidia V.; Ostrov, David A. Prediction of Off-Target Effects on Angiotensin-Converting Enzyme 2. SLAS Discovery. 2011, 16 (8): 878–885. doi:10.1177/1087057111413919
.
- ^ Li, Minghui; Zhao, Chaoyue; Shi, Jialu; Wang, Xun; Liu, Yuanchen; Zhao, Xiaoyu; Cai, Guonan; Chu, Hin; Wang, Pengfei. Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes. Emerging Microbes & Infections. 2024-12-31, 13 (1). ISSN 2222-1751. PMC 11421165
. PMID 39258934. doi:10.1080/22221751.2024.2404166
.
- ^ Sun, Cheng-Pu; Chiu, Chi-Wen; Wu, Ping-Yi; Tsung, Szu-I; Lee, I-Jung; Hu, Chih-Wei; Hsu, Min-Feng; Kuo, Tzu-Jiun; et al. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. Molecular Therapy. 2023, 31 (11): 3322–3336. PMC 10638075
. PMID 37689971. doi:10.1016/j.ymthe.2023.09.002
.
- ^ Blachier, Simon; Vaney, Marie-Christine; Conquet, Laurine; Staropoli, Isabelle; Fernández, Ignacio; Giraud, Emilie; Arbabian, Atousa; Michel, Vincent; Szilagyi, Fruzsina; Guez, Salomé; Boucharlat, Alix; Chiaravalli, Jeanne; Tran-Rajau, Jaouen; Dufour, Evelyne; Haouz, Ahmed; Petres, Stéphane; Planas, Delphine; Montagutelli, Xavier; Agou, Fabrice; Lafaye, Pierre; Ayme, Gabriel; Schwartz, Olivier; Rey, Felix A.; Enninga, Jost; Brelot, Anne. Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo (PDF). Nature Communications. 2025-11-21, 16 (1) [2026-10-18]. ISSN 2041-1723. PMC 12638815
. PMID 41271706. doi:10.1038/s41467-025-65144-w
.
- ^ 71.0 71.1 Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA. Emergence and evolution of the renin-angiotensin-aldosterone system.. J Mol Med (Berl). 2012, 90 (5): 495–508. PMC 3354321
. PMID 22527880. doi:10.1007/s00109-012-0894-z.
- ^ Rivière G, Michaud A, Corradi HR, Sturrock ED, Ravi Acharya K, Cogez V; et al. Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active.. Gene. 2007, 399 (1): 81–90. PMC 7127174
. PMID 17597310. doi:10.1016/j.gene.2007.05.010.
- ^ Bibiana S O F, Vargas-Pinilla P, Amorim CEG, Sortica VA, Bortolini MC. ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2.. Genet Mol Biol. 2020, 43 (2): e20200104. PMC 7278419
. PMID 32520981. doi:10.1590/1678-4685-GMB-2020-0104.
外部連結
[编辑]- Human ACE2 genome location and ACE2 gene details page in the UCSC Genome Browser.